IND-SWIFT LABORATORIES LTD.

Ind-Swift Laboratories Ltd is upgrading its Jammu manufacturing facility to EU-GMP/PICS standards to meet increased export demand. This upgrade, expected to be completed by early 2028 with an investment of approximately ₹45 crores, aims to generate an additional revenue of ₹100 crores from FY 2029-30 onwards from European and other regulated markets. The facility, currently WHO-GMP and ISO 9001:2008 compliant, will expand its market reach to the Rest of the World, supporting both CDMO and own branding businesses. The company recently reported strong Q1 FY27 financial results, with operating income growing 21.16% YoY and PAT (excluding exceptional items) jumping 2.04 times YoY.

Ind-Swift Laboratories Ltd has submitted its Monitoring Agency Report for the quarter ended June 30, 2026, concerning the utilization of proceeds from its preferential issue. The report, prepared by CARE Ratings Limited, confirms no deviation from the stated objects of the issue. The preferential issue aggregated to Rs. 314.60 crore. The report has been reviewed by the Audit Committee and taken on record by the Board of Directors.

Ind-Swift Laboratories Ltd announced robust Q1 FY27 results, with operating EBITDA surging 2.85x year-on-year to ₹33.32 crore and EBITDA margin expanding to 17.91%. Profit After Tax (PAT) excluding exceptional items jumped 2.04x YoY to ₹24.68 crore, with PAT margin improving to 13.26%. The company highlighted its transformation into a focused, debt-free formulations manufacturer, with significant contributions expected from new CDMO partnerships and product commercializations. Key milestones include the commercialization of Viatris, Manx, and Arrotex CDMO partnerships, expected to add ₹200-220 crore in FY27. The company also saw growth in its global dossier pipeline and product registrations, and is progressing the upgrade of its Samba manufacturing facility to EU-GMP and PIC/S standards. Ind-Swift projects over 50% revenue growth in FY27 and a medium-term CAGR of 20-25%.

Ind-Swift Laboratories Ltd has filed a Statement of NIL Deviation for the quarter ended June 30, 2026, confirming no variation in the use of funds raised through a Preferential Issue of Convertible Warrants. The company raised ₹255.61 Crores out of a total issue size of ₹314.60 Crores. A note clarifies that ₹58.99 Crores became non-receivable as an allottee failed to exercise its conversion rights, revising the monitored amount to ₹255.61 Crores. Funds were utilized for business expansion, investments in subsidiaries, working capital, and general corporate purposes, with no deviation from the original allocation.

Ind-Swift Laboratories Ltd announced that its Board of Directors, in a meeting held on August 10, 2026, approved the standalone and consolidated un-audited financial results for the quarter ended June 30, 2026. The company also approved the sale of approximately 40 Bighas (10 acres) of land in Village Behra, Derabassi, Punjab, for a consideration of ₹17.50 Crore. This land was initially purchased for a manufacturing facility but was found unsuitable for finished dosages due to international regulatory requirements. The sale is expected to be completed within nine months. The financial results and limited review reports have been submitted to the exchanges and will be available on the company's website.

Ind-Swift Laboratories' consolidated net profit for Q1 FY27 (quarter ended June 30, 2026) jumped 181% year-on-year to ₹24.68 Cr from ₹8.77 Cr, well ahead of the 25.4% YoY rise in revenue to ₹191.45 Cr (from ₹152.73 Cr). Sequentially, revenue grew 12.8% and PAT rose 63% over Q4 FY26. Standalone tells the same story — PAT of ₹24.44 Cr, up ~201% YoY on revenue of ₹186.08 Cr — the ~20-point gap versus consolidated growth traces to joint-venture consolidation scope rather than any divergence in the underlying operating story. The gain is almost entirely margin-led: consolidated OPM (EBITDA margin) expanded to roughly 17.5% from just 2.36% a year ago and 9.08% last quarter, with standalone EBITDA at ₹33.32 Cr against ₹8.44 Cr in Q1 FY26 (per the company's own disclosure). Consolidated NPM rose to ~12.9% from 5.24% YoY. A net exceptional loss of ₹0.24 Cr (₹23.58 Lakh, balances written back/off) was booked this quarter versus nil a year ago, but it is too small to move the growth number — adjusted PAT growth is ~184% YoY, effectively unchanged from the reported 181%. There is no analyst consensus or brokerage preview available for this stock, and the company has issued no formal forward guidance on record, so the print can only be judged against its own trend — a clear multi-quarter margin re-rating (OPM: 2.36% → 9.08% → 17.5%) rather than a one-off spike. Management's own note attributes the quarter to higher EBITDA generation but gives no line-by-line driver beyond the EBITDA and PAT figures disclosed. Alongside the results, the board approved sale of a ~10-acre non-operational land parcel in Derabassi for ₹17.50 Cr (to be realised over 9 months) — unconnected to this quarter's operating performance — while the company is separately progressing a ₹137.2 Cr preferential warrant issue to the promoter group and a ₹40 Cr warehouse-construction MoU, pointing to an active capital-raising and capacity-expansion phase running alongside the margin improvement.

Ind-Swift Laboratories Ltd announced that its shareholders have approved amendments to the company's Article of Association via special resolutions passed through e-voting at an Extra-Ordinary General Meeting held on August 5th, 2026. The amendments pertain to the retirement of Directors by rotation and their eligibility for re-appointment, aligning them with Section 152 of the Companies Act, 2013, SEBI LODR Regulations, 2015, and other applicable laws. The company has submitted the requisite disclosures as per SEBI LODR Regulations.

Ind-Swift Laboratories Ltd has announced that its Board of Directors will convene on August 10, 2026. The primary agenda item for this meeting is to consider, approve, and take on record the Un-Audited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026. The company has also confirmed that prior notification regarding the trading window closure was issued on June 26, 2026. Further details are available on the company's website.

Ind-Swift Laboratories Ltd has issued a Corrigendum to its Extra Ordinary General Meeting (EGM) Notice, originally dated July 10, 2026, and scheduled for August 5, 2026. The corrigendum addresses changes to Item No. 1 of the EGM Notice and its Explanatory Statement, specifically concerning the proposed preferential issue of 70,00,000 Fully Convertible Warrants to promoters. These changes are made pursuant to observations received from BSE and NSE. The revised Explanatory Statement details the utilization of proceeds for business expansion, R&D, technology upgrades, and investment in a subsidiary.

Ind-Swift Laboratories Limited's Preferential Issue Committee has approved a Corrigendum to the EGM Notice. The EGM, scheduled for August 5, 2026, will seek member approval for a preferential issue of Fully Convertible Warrants. The corrigendum addresses modifications required in the Explanatory Statement, following queries from NSE and BSE. All other terms of the original EGM notice remain unchanged.